NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Juno Therapeutics Inc. (“Juno Therapeutics” or the “Company”) (NASDAQ: JUNO) concerning possible violations of federal securities laws.
On June 7, 2016, Juno announced that three patients had died during a clinical trial for the Company’s chemotherapy drug, fludarabine. Following this news, shares of Juno were down more than 31% on intraday trading on July 8, 2016. To obtain additional information about the investigation, go to:
or contact Eduard Korsinsky, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.